Promising Leap Forward in Research on PSC and Bile Duct Cancer
Promising Leap Forward in Research on PSC and Bile Duct Cancer
Dr Edward Jarman
We are pleased to share an important update from the research project, 'Cell states in the transition from PSC to bile duct cancer,' led by Dr Edward Jarman. This study, which we proudly fund, focuses on a critical area: understanding the changes that occur when PSC progresses to cholangiocarcinoma (CCA), a type of bile duct cancer.
The team has been using advanced laboratory modelling to observe this complex process. Through this, they have successfully identified a distinct 'signature' (a pattern of cell changes) that happens during the transition.
A key finding is the identification of a protein called COX2 as a potential marker of this process. In a significant step, Dr Jarman has shown that a subset of PSC patients have cells that are positive for COX2 in their bile ducts. This finding is crucial because it means that what the scientists are seeing in the lab matches what is actually happening inside the bodies of people with PSC.
Dr Jarman notes that this represents an ‘appreciable leap forward’ for the project’s goal to define the mechanisms of PSC-CCA transition and determine whether these early changes are detectable in PSC patients.
This work is an exciting step forward. By defining these mechanisms and identifying markers like COX2, this research may eventually help us to detect early changes in people with PSC who could be at higher risk. This is vital for accelerating the development of new ways to screen, prevent, or treat the progression to CCA.
Turning Ambition into Action in 2026:
Our Fortnight in Focus
At PSC Support, we want a world without PSC. We work tirelessly behind the scenes to drive research and improve lives. Here is a snapshot of what we've been up to:
Global Research Preparation: We helped develop patient consent documentation for a global PSC research initiative coming to the UK in 2026 so it aligns with UK patient needs.
Representing the Patient Voice: We provided the patient perspective in a panel interview with a major funder regarding a potential new clinical trial for PSC.
Patient-Led Governance: We convened a Patient Panel to review a plans for a new UK study, ensuring the research focuses on the practical needs and safety concerns of people with PSC.
Global Advocacy: We had a late-night meeting to finalise a joint abstract with PSC Partners Seeking a Cure (USA) to present our shared patient survey data at a major European conference.
Regulator Collaboration: We participated in a national workshop with regulators to identify ways to speed up access to new rare disease treatments.
Scientific Leadership: We received excellent editorial feedback on a new textbook chapter about PSC we've been working on with European Reference Network for Rare Liver Diseases experts to improve clinical knowledge of PSC.
Research Governance: We initiated a project to update our research governance protocols and migrate historical research data into our new Grant Management System, ensuring all the research we fund is accurately recorded.
Supporting our Fundraisers: We simplified the process for applying for a Great North Run this year, making it easier for fundraisers and more efficient for PSC Support - win/win!